HLOS.F Stock Overview
Engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Healios K.K. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1.21 |
| 52 Week High | JP¥1.59 |
| 52 Week Low | JP¥0.93 |
| Beta | 0.91 |
| 11 Month Change | 30.68% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -93.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| HLOS.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.3% | 1.0% |
| 1Y | n/a | 8.2% | 23.6% |
Return vs Industry: Insufficient data to determine how HLOS.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how HLOS.F performed against the US Market.
Price Volatility
| HLOS.F volatility | |
|---|---|
| HLOS.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: HLOS.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HLOS.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 64 | Hardy Kagimoto | www.healios.co.jp |
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013.
Healios K.K. Fundamentals Summary
| HLOS.F fundamental statistics | |
|---|---|
| Market cap | US$99.81m |
| Earnings (TTM) | -US$34.31m |
| Revenue (TTM) | US$771.47k |
129.4x
P/S Ratio-2.9x
P/E RatioIs HLOS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLOS.F income statement (TTM) | |
|---|---|
| Revenue | JP¥124.00m |
| Cost of Revenue | JP¥13.00m |
| Gross Profit | JP¥111.00m |
| Other Expenses | JP¥5.63b |
| Earnings | -JP¥5.51b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | -61.19 |
| Gross Margin | 89.52% |
| Net Profit Margin | -4,447.58% |
| Debt/Equity Ratio | 119.1% |
How did HLOS.F perform over the long term?
See historical performance and comparison